BIVI - BioVie to present neurodegenerative research at Alzheimer’s Associate’s International Conference

(NewsDirect)

BioVie Chief Medical Officer Dr. JoePalumbo joins Natalie Stoberman from the Proactive newsroom to sharehow the company plans to present its research on neurodegenerativediseases at the Alzheimer’s Associate’s International Conference(AAIC) to be held in Amsterdam July 16-20.

Dr. Palumbo says BioVie will showcase itsNE3107 molecule and discuss how patients with clinical dementiatreated with NE3107 for three months were able to see significantreductions in the level of DNA methylation and how the correlation ofthose reductions led to improvements in various cognitive measures.

Dr. Palumbo explains that neuroinflammation, insulinresistance, and oxidative stress are common features in the majorneurodegenerative diseases, including Alzheimer’s Disease,Parkinson’s Disease, dementia and ALS. He says NE3107 is an oralsmall molecule, blood-brain permeable, compound with potentialanti-inflammatory, insulin sensitizing, and ERK-binding propertiesthat may allow it to selectively inhibit ERK-, NF?B- andTNF-stimulated inflammation. NE3107’s potential to inhibitneuroinflammation and insulin resistance forms the basis for thecompany’s work testing the molecule in AD and PDpatients.

Contact Details

Proactive USA

+1347-449-0879

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.